- Home
- OMER vs NGS Comparison
OMER vs NGS Comparison
Compare OMER & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- NGS
- Stock Information
- Founded
- OMER 1994
- NGS 1998
- Country
- OMER United States
- NGS United States
- Employees
- OMER N/A
- NGS N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- NGS Oilfield Services/Equipment
- Sector
- OMER Health Care
- NGS Energy
- Exchange
- OMER Nasdaq
- NGS Nasdaq
- Market Cap
- OMER 274.3M
- NGS 328.4M
- IPO Year
- OMER 2009
- NGS 2002
- Fundamental
- Price
- OMER $7.61
- NGS $27.55
- Analyst Decision
- OMER Strong Buy
- NGS Strong Buy
- Analyst Count
- OMER 6
- NGS 3
- Target Price
- OMER $27.50
- NGS $33.67
- AVG Volume (30 Days)
- OMER 8.1M
- NGS 52.5K
- Earning Date
- OMER 11-12-2025
- NGS 11-13-2025
- Dividend Yield
- OMER N/A
- NGS 1.45%
- EPS Growth
- OMER N/A
- NGS 33.85
- EPS
- OMER N/A
- NGS 1.42
- Revenue
- OMER N/A
- NGS $164,109,000.00
- Revenue This Year
- OMER N/A
- NGS $9.86
- Revenue Next Year
- OMER N/A
- NGS $14.21
- P/E Ratio
- OMER N/A
- NGS $19.49
- Revenue Growth
- OMER N/A
- NGS 14.77
- 52 Week Low
- OMER $2.95
- NGS $16.73
- 52 Week High
- OMER $13.60
- NGS $29.74
- Technical
- Relative Strength Index (RSI)
- OMER 62.09
- NGS 54.74
- Support Level
- OMER $7.43
- NGS $25.71
- Resistance Level
- OMER $12.10
- NGS $28.62
- Average True Range (ATR)
- OMER 0.69
- NGS 0.91
- MACD
- OMER 0.17
- NGS 0.08
- Stochastic Oscillator
- OMER 44.09
- NGS 65.37
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.